No Data
No Data
Day One Biopharm Is Maintained at Overweight by Piper Sandler
Day One Biopharm Is Maintained at Overweight by Piper Sandler
Day One Biopharm Price Target Maintained With a $40.00/Share by Piper Sandler
Day One Biopharm Price Target Maintained With a $40.00/Share by Piper Sandler
Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Maintains $40 Price Target
Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and maintains $40 price target.
Piper Sandler Keeps Their Buy Rating on Day One Biopharmaceuticals (DAWN)
Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals(DAWN.US) Director Sells US$131.88K in Common Stock
$Day One Biopharmaceuticals(DAWN.US)$ Director Ramasastry Saira sold 10,000 shares of common stock on Jun 21, 2024 at an average price of $13.1877 for a total value of $131.88K.Source: Announcement Wh